



## Jazz Pharmaceuticals, Inc. Announces Initial Public Offering

May 31, 2007

PALO ALTO, Calif., May 31 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals, Inc. today announced the pricing of its initial public offering of 6,000,000 shares of common stock at \$18.00 per share. All of the shares are being offered by Jazz Pharmaceuticals. Jazz Pharmaceuticals' common stock is expected to begin trading on the NASDAQ Global Market under the trading symbol "JAZZ" on Friday, June 1, 2007.

Morgan Stanley & Co. Incorporated and Lehman Brothers Inc. are acting as joint bookrunners and joint lead managers. Co-managers for the offering are Credit Suisse Securities (USA) LLC and Natexis Bleichroeder Inc. Jazz Pharmaceuticals has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares to cover over-allotments, if any.

The offering of these securities is being made only by means of a written prospectus, copies of which may be obtained by contacting Morgan Stanley & Co. Incorporated, Attention: Prospectus Department, 180 Varick Street, New York, NY 10014, by telephone at 1-212-761-6775, or by email: [prospectus@morganstanley.com](mailto:prospectus@morganstanley.com); or Lehman Brothers Inc., c/o Broadridge, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at: 1-888-603-5847, by email: [qiana.smith@broadridge.com](mailto:qiana.smith@broadridge.com), or by fax at 1-631-254-7268.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on May 31, 2007. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Jazz Pharmaceuticals, Inc.

Jazz Pharmaceuticals is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry.

SOURCE Jazz Pharmaceuticals, Inc.

-0- 05/31/2007

/CONTACT: Karen L. Bergman, +1-650-575-1509, or Michelle Corral, +1-415-794-8662, both of BCC Partners for Jazz Pharmaceuticals, Inc.; or Jim Karrels, Senior Director of Finance of Jazz Pharmaceuticals, Inc., +1-650-496-3777, [investorinfo@jazzpharma.com](mailto:investorinfo@jazzpharma.com) /  
/Web site: <http://www.jazzpharmaceuticals.com> /  
(JAZZ)

CO: Jazz Pharmaceuticals, Inc.

ST: California

IN: HEA MTC BIO

SU: OFR

AS-CC

-- AQTH192 --

7982 05/31/2007 22:58 EDT <http://www.prnewswire.com>